DRG Market Assessment reports

Focal segmental glomerulosclerosis (FSGS) is a kidney disease in which scarring occurs to the glomeruli. Patients with FSGS typically present with nephrotic syndrome, involving edema and…

The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…

Graft versus host disease (GVHD) is a potentially life-threatening complication of allogeneic hematopoietic stem-cell transplantation (HSCT). GVHD is a systemic inflammatory reaction triggered by…

NASH is an increasingly prevalent disease characterized by excess lipid (steatosis) in the liver, resulting in inflammation and eventually liver fibrosis. Ensuing complications can include liver…

Endometrial cancer is the sixth most common cancer in women worldwide. While the majority of patients present with early stage disease at diagnosis, efficacious therapeutic options for advanced or…

Spinal cord injury (SCI) is a catastrophic event, often as a result of trauma, that typically results in long-lasting motor, sensory, and/or autonomic deficits. The nature of such deficits is…

Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Symptoms include severe anemia, weakness, fatigue, and splenomegaly…

Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity…

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia (AML). Although…

The coronavirus disease 2019 (COVID-19) Epidemiology Forecaster is a fully customizable SEIR(susceptible, exposed, infectious, recovered) model that allows users to develop scenario-based global…

A range of oral and nonoral triptans (e.g., sumatriptan) are available for the acute treatment of migraine and are entrenched in medical practice. However, triptans have noted clinical shortcomings…

In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…